Adalimumab
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Adalimumab: TNF-alpha inhibitor → hypermobility of coccyx
One-Sentence Summary
Adalimumab is a TNF-alpha inhibitor (a biologic monoclonal antibody) marketed in Australia as an injectable product. The TxGNN model predicts it may be effective for hypermobility of coccyx, but no clinical trials and no publications directly support this prediction, so it remains a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hypermobility of coccyx |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug. Adalimumab is known to be a monoclonal antibody that neutralises TNF-alpha, a cytokine that drives inflammation and structural damage in several immune-mediated conditions, including those affecting the axial skeleton and sacroiliac region.
A plausible but unsupported link is that this TNF-alpha blockade could affect inflammatory conditions around the spine and pelvis. However, coccygeal hypermobility is generally mechanical or post-traumatic rather than inflammatory, so the mechanistic rationale is weak. The high TxGNN score is a computational output and should not be read as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for hypermobility of coccyx.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10399H | Hadlima | Injection 40 mg in 0.8 mL pre-filled syringe | Not recorded in the local data |
At least the data compiled for this report show one valid single-ingredient licence and no cancelled or non-marketed licences.
Safety Considerations
Drug Interactions (100 interactions were found in the interaction database; the main ones are listed below):
- Major: corticosteroids (betamethasone, budesonide, dexamethasone, hydrocortisone, prednisolone, prednisone, triamcinolone including ophthalmic), deferiprone, and the radiopharmaceuticals ibritumomab tiuxetan, iobenguane (I-131), tositumomab and tositumomab (I-131).
- Moderate: metronidazole, tinidazole, rosuvastatin, simvastatin.
- Minor: zinc acetate, zinc gluconate, zinc sulfate.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, as these were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. No trials or publications address hypermobility of coccyx, and the proposed mechanism is weak because the condition is mainly mechanical rather than TNF-driven.
To proceed, the following is needed:
- Any clinical or observational evidence linking TNF inhibition to coccygeal hypermobility, or a clear pathophysiological rationale
- Detailed mechanism of action data
- Warnings and contraindications from the TGA-approved Product Information
- Confirmation of the approved indications for the Australian product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.